Merck KGaA (ETR:MRK)
Germany
· Delayed Price · Currency is EUR | Market Cap | 63.33B |
| Revenue (ttm) | 20.96B |
| Net Income (ttm) | 2.53B |
| Shares Out | 434.78M |
| EPS (ttm) | 5.83 |
| PE Ratio | 24.99 |
| Forward PE | 17.85 |
| Dividend | 2.20 (1.50%) |
| Ex-Dividend Date | Apr 27, 2026 |
| Volume | n/a |
| Average Volume | 413,575 |
| Open | 145.65 |
| Previous Close | 147.00 |
| Day's Range | 142.55 - 146.50 |
| 52-Week Range | 100.70 - 147.70 |
| Beta | 0.81 |
| RSI | 74.33 |
| Earnings Date | Aug 6, 2026 |
About Merck KGaA
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry... [Read more]
Financial Performance
In 2025, Merck KGaA's revenue was 21.10 billion, a decrease of -0.26% compared to the previous year's 21.16 billion. Earnings were 2.61 billion, a decrease of -6.09%.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for MRK stock is "Buy." The 12-month stock price target is €144.00, which is a decrease of -1.13% from the latest price.
News
Merck KGaA Transcript: M&A announcement
The acquisition of Bio-Techne for $73 per share aims to accelerate growth in Life Science by combining complementary portfolios, with EUR 140 million in cost synergies expected within three years. The deal is immediately margin accretive, enhances innovation, and strengthens U.S. presence.
Merck KGaA Slides: M&A announcement
Merck KGaA has posted slides in relation to its latest quarterly earnings report, which was published on June 25, 2026.
Merck KGaA Press release: M&A announcement
Merck KGaA issued a press release on June 25, 2026, disclosing material business information to investors.
Germany's Merck Is Buying Bio-Techne for $11.3 Billion
Bio-Techne stock jumps, with Germany's Merck KGaA buying the company at a 24% premium.
Germany's Merck to buy Bio-Techne for $73 per share
Merck KGaA has agreed to acquire biotech firm Bio-Techne Corp for $73 per share in cash, the German science and healthcare firm said in a statement on Thursday.
Germany's Merck to Buy Bio-Techne for $11 Billion
Merck KGaA offered $73 a share in cash to buy Bio-Techne, representing a 24% premium to the U.S. lab-tools supplier's closing price Wednesday.
Merck KGaA, Darmstadt, Germany, Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies.
Merck Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies
DARMSTADT, Germany--(BUSINESS WIRE)--Merck Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies.
Merck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer.
Merck KGaA Earnings Call Transcript: Q1 2026
Solid organic growth in Life Science and Electronics offset Healthcare declines, with upgraded 2026 guidance reflecting strong Process Solutions and robust cash flow. One-off gains and disciplined cost management supported margins despite FX headwinds.
Merck KGaA Quarterly report: Q1 2026
Merck KGaA has published its Q1 2026 quarterly earnings report on May 13, 2026.
Merck KGaA Slides: Q1 2026
Merck KGaA has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 13, 2026.
Merck KGaA Earnings release: Q1 2026
Merck KGaA released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Merck KGaA Earnings release: Q1 2026
Merck KGaA released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Merck KGaA Slides: Q1 2026
Merck KGaA has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 13, 2026.
Merck KGaA Slides: Investor presentation
Merck KGaA has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
Germany's Merck KGaA Raises Guidance
The outlook lift comes on expectations of stronger momentum in the group's life-sciences unit, resilience in healthcare, as well as its first-quarter performance and market conditions.
Merck KGaA lifts earnings outlook on stronger Life Science momentum
Germany's Merck KGaA on Wednesday raised its 2026 adjusted operating profit guidance range, citing stronger momentum at its Life Science division and delayed competition for its Mavenclad multipl...
Merck KGaA, Darmstadt, Germany, Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT0...
Merck KGaA Transcript: AGM 2026
AGM 2026 highlighted strong financial growth, strategic investments in bioprocessing, rare diseases, and AI, and a leadership transition from Garijo to Beckmann. A stable EUR 2.2 dividend per share was proposed, with continued focus on resilience and innovation.
TrumpRx lists many medicines at prices higher than paid in UK
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those ...
Merck KGaA Earnings Call Transcript: Q4 2025
Solid organic growth in Life Science and Healthcare offset macro and FX headwinds, with Electronics rebounding on AI-driven demand. 2026 guidance anticipates stable margins, mid-single-digit Life Science growth, and continued strength in Semiconductor Materials.
Merck KGaA Annual report: Q4 2025
Merck KGaA has published its Q4 2025 annual report on March 5, 2026.
Merck KGaA Earnings release: Q4 2025
Merck KGaA released its Q4 2025 earnings on March 5, 2026, summarizing the period's financial results.
Merck KGaA Quarterly report: Q4 2025
Merck KGaA has published its Q4 2025 quarterly earnings report on March 5, 2026.